Drug Trial Radar · NCT03705065
Bupivacaine HCl PK and Safety in Augmentation Mammoplasty
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 19, 2018
Primary completion
Oct 8, 2018
Study completion Nov 5, 2018
Sponsor
- Lead sponsor
- Heron TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
Conditions
- Postoperative Pain
Interventions
Bupivacaine HClDrug
Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Through 72 hours after start of study drug administration
- AUClastTime frame: Through 72 hours after start of study drug administration
- AUCinfTime frame: Through 72 hours after start of study drug administration
- TmaxTime frame: Through 72 hours after start of study drug administration
- λzTime frame: Through 72 hours after start of study drug administration
- t1/2elTime frame: Through 72 hours after start of study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hermann Drive Surgical Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.